Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03995121 · ClinicalTrials.gov registry record
SV2 PET Imaging With [11C]APP311
A clinical trial of Healthy and Cannabis Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT03995121: Recruiting study of Healthy and Cannabis Use Disorder, sponsored by Yale University.
NCT03995121 is a study of Healthy and Cannabis Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 250 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03995121, a study of Healthy and Cannabis Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Primary Outcome
To compare synaptic vesicle protein 2A (SV2A) density in two groups of subjects with psychiatric disorders (namely 'schizophrenia and other psychotic disorders', and 'cannabis use disorder') to that in healthy controls using the PET radiotracer 11C-APP311
Conditions Studied
Interventions
- DRUG [11C]APP311
Study Locations (1)
Connecticut
- Conneticut Mental Health Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2026-12 |
What NCT03995121 shows while recruiting
NCT03995121 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (61% lower).
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which [11C]APP311 is the first listed.
NCT03995121 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT03995121 about?
NCT03995121 is a clinical study titled "SV2 PET Imaging With [11C]APP311". The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
What is the current status of trial NCT03995121?
This trial is currently recruiting. The enrollment target is 250 participants. The study started on 2017-12-01. Estimated completion is 2026-12.
What conditions does trial NCT03995121 study?
This clinical trial studies the following conditions: Healthy, Cannabis Use Disorder, Schizophrenia and Other Psychotic Disorders.
What interventions are being tested in trial NCT03995121?
The interventions under investigation include: [11C]APP311 (DRUG).
Who is sponsoring clinical trial NCT03995121?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03995121 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03995121's enrollment target sits among peer trials
250 99th of 1090 higher than 990 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI